Cys-TAT(47-57)
CAS No. 583836-55-9
Cys-TAT(47-57) ( Cys-[HIV-Tat (47-57)] )
Catalog No. M29884 CAS No. 583836-55-9
Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.This peptide corresponds to the protein transduction domain of the TAT protein.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameCys-TAT(47-57)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.This peptide corresponds to the protein transduction domain of the TAT protein.
-
DescriptionCys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.This peptide corresponds to the protein transduction domain of the TAT protein.
-
SynonymsCys-[HIV-Tat (47-57)]
-
PathwayMicrobiology/Virology
-
TargetHIV
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number583836-55-9
-
Formula Weight1662
-
Molecular FormulaC67H124N34O14S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Bertrand SJ, et al. HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol. 2013 Oct;248:228-35.
molnova catalog
related products
-
NBD-14189
NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63nM against some clinical isolates.
-
ABX464
ABX464 (ABX-464, ABX 464) is a novel class of anti-HIV small molecule targeting Rev-mediated viral RNA biogenesis.
-
Escin IA;Aescin IA
Escin IA is a triterpene saponin isolated from horse chestnut which inhibits HIV-1 protease with IC50 values of 35 μM. Escin IA has anti-TNBC metastasis activity and its action mechanisms involved inhibition of epithelial-mesenchymal transition process by down-regulating LOXL2 expression.